"I want patients to understand their options and have choices."
- Ann H. Partridge, MD, MPH
"We need to tailor therapies better for individual patients….the problem is that we overtreat the many to benefit the few."
- Lawrence J. Solin, MD
"There is risk both with treatment and with treatment deescalation, and we need to be able to quantify that trade off in a much better way for an individual patient."
- Shelley Hwang, MD, MPH
"The next few years will witness the publication of major trial results and potentially chart a new course of DCIS management."
- Lars J. Grimm, MD, MHS
When we talk about progress in breast cancer, we often point to the encouraging news that deaths from invasive breast cancer have steadily declined over recent decades—thanks to advances in detection, treatment and care.
But for DCIS, there is weak or even no evidence that our current treatments actually reduce the chance of dying from breast cancer. A new study published in Breast Cancer Research looked closely at this question, and the results raise important concerns.
